Core Insights - Nektar Therapeutics will host an investor call and live webcast to discuss topline results from the 36-week maintenance period of the Phase 2b REZOLVE-AD clinical trial for rezpegaldesleukin, targeting moderate-to-severe atopic dermatitis on February 10, 2026 [1] Company Overview - Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments for autoimmune and chronic inflammatory diseases [3] - The lead product candidate, rezpegaldesleukin (REZPEG or NKTR-358), is a first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials: one for atopic dermatitis and another for alopecia areata, along with a Phase 2 trial for Type 1 diabetes mellitus [3] - Nektar's pipeline includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody, bispecific programs NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422 [3] - The company is also evaluating NKTR-255, an investigational IL-15 receptor agonist aimed at enhancing the immune system's ability to combat cancer, in several ongoing clinical trials [3]

Windward Bio and Qyuns Therapeutics announce licensing agreement for WIN027, a highly potent, long-acting bispecific antibody with best-in-disease potential in respiratory and dermatologyWIN027 blocks 2 well-validated and synergistic drivers of inflammation — TSLP and IL‑13 — that play integral roles in respiratory and dermatology diseasesWIN027 deepens the company’s immunology pipeline and is currently in Phase 1 BASEL, Switzerland, Dec. 21, 2025 (GLOBE NEWSWIRE) -- Windward Bio AG, a private, clinical-sta ...